A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study

Autor:	F. Donskov, Toni K. Choueiri, Wanling Xie, Jennifer J. Knox, G. A. Bjarnason, U. N. Vaishampayan, Lori Wood, B. I. Rini, Christian K. Kollmannsberger, Min-Han Tan, D. Y. Heng
Rok vydání:	2010
Předmět:	Oncology Sorafenib Cancer Research medicine.medical_specialty education.field_of_study Everolimus Bevacizumab Sunitinib business.industry medicine.medical_treatment Population Temsirolimus Targeted therapy Surgery Axitinib Internal medicine medicine education business medicine.drug
Zdroj:	Journal of Clinical Oncology. 28:4523-4523
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2010.28.15_suppl.4523
Popis:	4523 Background: Outcomes of second-line targeted therapy (TT) after failure of initial anti-VEGF therapy have not been well characterized. Outcome data as well as existing prognostic criteria in this population were evaluated. Methods: Between 2005- 2009, data from patients (pts) treated with initial VEGF TT were collected from 12 cancer centers. The subset of pts who failed their first anti-VEGF therapy and then were subsequently treated with another targeted agent was analyzed for outcomes and prognostic factors. Results: From the initial cohort of 1,084 pts, 321 pts met inclusion criteria and were included in this analysis. The second-line TT was sunitinib (32%), sorafenib (45%), axitinib (3%), bevacizumab (3%), temsirolimus (11%) or everolimus (6%). From the start of the second-line targeted therapy, the median follow-up was 20.6 months (mos), the median progression-free survival was 3.7 mos, and the median overall survival (mOS) was 12.3 mos (95%CI 10-13.3 mos). Using known poor prognostic factors f...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4dc088d2775f001203b0392572277121 https://doi.org/10.1200/jco.2010.28.15_suppl.4523 Zobrazit plný text záznamu